| 000 | 01845 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250515230613.0 | ||
| 264 | 0 | _c20101105 | |
| 008 | 201011s 0 0 eng d | ||
| 022 | _a0008-543X | ||
| 024 | 7 |
_a10.1002/cncr.25216 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRigacci, Luigi | |
| 245 | 0 | 0 |
_aOxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma. _h[electronic resource] |
| 260 |
_bCancer _cOct 2010 |
||
| 300 |
_a4573-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Murine-Derived |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCytarabine _xadministration & dosage |
| 650 | 0 | 4 |
_aDexamethasone _xadministration & dosage |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHodgkin Disease _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, B-Cell _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOrganoplatinum Compounds _xadministration & dosage |
| 650 | 0 | 4 | _aOxaliplatin |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aSalvage Therapy |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aFabbri, Alberto | |
| 700 | 1 | _aPuccini, Benedetta | |
| 700 | 1 | _aChitarrelli, Ida | |
| 700 | 1 | _aChiappella, Annalisa | |
| 700 | 1 | _aVitolo, Umberto | |
| 700 | 1 | _aLevis, Alessandro | |
| 700 | 1 | _aLauria, Francesco | |
| 700 | 1 | _aBosi, Alberto | |
| 773 | 0 |
_tCancer _gvol. 116 _gno. 19 _gp. 4573-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cncr.25216 _zAvailable from publisher's website |
| 999 |
_c19920396 _d19920396 |
||